Provided by Tiger Fintech (Singapore) Pte. Ltd.

NKGEN BIOTECH INC

0.1913
-0.3245-62.91%
Post-market: 0.1900-0.0013-0.68%19:59 EST
Volume:8.44M
Turnover:2.31M
Market Cap:8.60M
PE:-0.04
High:0.5099
Open:0.5099
Low:0.1903
Close:0.5158
Loading ...

NKGen to Transfer Listing to OTC Markets; Shares Drop

MT Newswires Live
·
9 hours ago

NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split

TIPRANKS
·
9 hours ago

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

GlobeNewswire
·
10 hours ago

BRIEF-Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program

Reuters
·
03 Mar

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

THOMSON REUTERS
·
03 Mar

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

GlobeNewswire
·
03 Mar

BRIEF-NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

Reuters
·
21 Feb

NKGen administers first troculeucel dose under compassionate use program

TIPRANKS
·
21 Feb

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

THOMSON REUTERS
·
21 Feb

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

GlobeNewswire
·
21 Feb

BRIEF-NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer’S Disease With Adventhealth Orlando As First East Coast Site

Reuters
·
19 Feb

NKGen Biotech appoints Anita Fletcher as PI for Phase 2a troculeucel trial

TIPRANKS
·
19 Feb

NKGen Appoints DR. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease With Adventhealth Orlando as First East Coast Site

THOMSON REUTERS
·
19 Feb

BRIEF-NKGen Biotech Publishes Phase 1 Troculeucel Clinical Trial Results

Reuters
·
13 Feb

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease

THOMSON REUTERS
·
13 Feb

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease

GlobeNewswire
·
13 Feb